MK-1248

MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research[1].

Product Specifications

UNSPSC

12352203

Target

TNF Receptor

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[MK-1248]

References & Citations

[1]Geva R, et al. First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer. 2020 Nov 15;126 (22) :4926-4935.